Cargando…

Management of acute coronary syndromes with fondaparinux

Fondaparinux is the first selective inhibitor of the coagulation factor Xa which is commercially avaliable for clinical use. It has been approved for the prevention of venous thromboembolism in patients undergoing orthopedic surgery and for the initial therapy of venous thromboembolism. In randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Wienbergen, Harm, Zeymer, Uwe
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2293968/
https://www.ncbi.nlm.nih.gov/pubmed/17703640